BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway

  • Sun, Tong (Department of Nuclear Medicine, The first Hospital of China Medical University) ;
  • Du, Bulin (Department of Nuclear Medicine, The first Hospital of China Medical University) ;
  • Diao, Yao (Department of Nuclear Medicine, The first Hospital of China Medical University) ;
  • Li, Xuena (Department of Nuclear Medicine, The first Hospital of China Medical University) ;
  • Chen, Song (Department of Nuclear Medicine, The first Hospital of China Medical University) ;
  • Li, Yaming (Department of Nuclear Medicine, The first Hospital of China Medical University)
  • Received : 2019.02.11
  • Accepted : 2019.05.13
  • Published : 2019.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

[18F]Fluorodeoxyglucose (FDG) PET/CT imaging has been widely used in the diagnosis of malignant tumors. ATPase family AAA domain-containing protein 2 (ATAD2) plays important roles in tumor growth, invasion and metastasis. However, the relationship between [18F]FDG accumulation and ATAD2 expression remains largely unknown. This study aimed to investigate the correlation between ATAD2 expression and [18F]FDG uptake in lung adenocarcinoma (LUAD), and elucidate its underlying molecular mechanisms. The results showed that ATAD2 expression was positively correlated with maximum standardized uptake value ($SUV_{max}$), total lesion glycolysis (TLG), glucose transporter type 1 (GLUT1) expression and hexokinase2 (HK2) expression in LUAD tissues. In addition, ATAD2 knockdown significantly inhibited the proliferation, tumorigenicity, migration, [18F]FDG uptake and lactate production of LUAD cells, while, ATAD2 overexpression exhibited the opposite effects. Furthermore, ATAD2 modulated the glycometabolism of LUAD via AKT-GLUT1/HK2 pathway, as assessed using LY294002 (an inhibitor of PI3K/AKT pathway). In summary, to explore the correlation between ATAD2 expression and glycometabolism is expected to bring good news for anti-energy metabolism therapy of cancers.

Keywords

References

  1. Siegel RL, Miller KD and Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68, 277-300
  2. Coudray N, Moreira AL, Sakellaropoulos T, Fenyo D, Razavian N and Tsirigos A (2018) Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med 24, 1559-1567 https://doi.org/10.1038/s41591-018-0177-5
  3. Yamasaki T, Nakazaki Y, Yoshida M and Watanabe Y (2011) Roles of conserved arginines in ATP-binding domains of AAA+ chaperone ClpB from Thermus thermophiles. FEBS J 278, 2395-2403 https://doi.org/10.1111/j.1742-4658.2011.08167.x
  4. Nouet C, Truan G, Mathieu L and Dujardin G (2009) Functional analysis of yeast bcs1 mutants highlights the role of Bcs1p-specific amino acids in the AAA domain. J Mol Biol 388, 252-261 https://doi.org/10.1016/j.jmb.2009.03.018
  5. Zheng L, Li T, Zhang Y et al (2015) Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep 33, 2337-2344 https://doi.org/10.3892/or.2015.3867
  6. Fouret R, Laffaire J, Hofman P et al (2012) A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res 18, 5606-5616 https://doi.org/10.1158/1078-0432.CCR-12-0505
  7. Alvarez JV, Belka GK, Pan T et al (2014) Oncogene pathway activation in mammary tumors dictates [18F]-FDG-PET uptake. Cancer Res 74, 7583-7598 https://doi.org/10.1158/0008-5472.CAN-14-1235
  8. Zou JX, Revenko AS, Li LB, Gemo AT and Chen HW (2007) ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A 104, 18067-18072 https://doi.org/10.1073/pnas.0705814104
  9. Zhang Y, Sun Y, Li Y et al (2013) ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol 20, 577-582 https://doi.org/10.1245/s10434-013-3027-1
  10. Fan Y, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285, 7324-7333 https://doi.org/10.1074/jbc.M109.035584
  11. Caron C, Lestrat C, Marsal S et al (2010) Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 29, 5171-5181 https://doi.org/10.1038/onc.2010.259
  12. Wu G, Liu H, He H et al (2014) miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer 14, 1-11 https://doi.org/10.1186/1471-2407-14-1
  13. Wan WN, Zhang YX, Wang XM et al (2014) ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. APJCP 15, 2777-2783
  14. Shang P, Meng FL, Liu YD and Chen XW (2015) Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. Tumor Biol 36, 4479-4485 https://doi.org/10.1007/s13277-015-3089-8
  15. Zhang MJ, Zhang CZ, Du WJ, Yang XZ and Chen ZP (2015) ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol 18, 1-6 https://doi.org/10.1007/s12094-015-1332-9
  16. Jadvar H, Alavi A, Gambhir SS (2009) [18F]FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50, 1820-1827 https://doi.org/10.2967/jnumed.108.054098
  17. Cho H, Lee YS, Kim J, Chung JY and Kim JH (2013) Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest 31, 607-615 https://doi.org/10.3109/07357907.2013.849722
  18. Chae YC and Kim JH (2018) Cancer stem cell metabolism: target for cancer therapy. BMB Rep 51, 319-326 https://doi.org/10.5483/BMBRep.2018.51.7.112
  19. Zhuo B, Li Y, Li Z et al (2015) PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. Biochem Biophys Res Commun 464, 401-406 https://doi.org/10.1016/j.bbrc.2015.06.092
  20. Wang H, Wang L, Zhang YJ, Wang J, Deng YB and Lin DG (2016) Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int 16, 9 https://doi.org/10.1186/s12935-016-0280-y
  21. Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S and Khochbin S (2013) Malignant genome reprogramming by ATAD2. Biochim Biophys Acta 1829, 1010-1014 https://doi.org/10.1016/j.bbagrm.2013.06.003
  22. Wu K, Wang W, Chen H, Gao W and Yu C (2019) Insulin promotes proliferation of pancreatic ductal epithelial cells by increasing expression of PLK1 through PI3K/AKT and NF-kB pathway. Biochem Biophys Res Commun 509, 925-930 https://doi.org/10.1016/j.bbrc.2018.12.182
  23. Tsai JS, Chao CH and Lin LY (2016) Cadmium activates multiple signaling pathways that coordinately stimulate Akt activity to enhance c-Myc mRNA stability. PLoS One 11, e0147011 https://doi.org/10.1371/journal.pone.0147011
  24. Hong SY, Yu FX, Luo Y and Hagen T (2016) Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Cell Signal 28, 377-383 https://doi.org/10.1016/j.cellsig.2016.01.011
  25. Stine ZE, Walton ZE, Altman BJ, Hsieh AL and Dang CV (2015) MYC, metabolism, and cancer. Cancer Discov 5, 1024-1039 https://doi.org/10.1158/2159-8290.CD-15-0507
  26. Wahlstrom T and Henriksson MA (2015) Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta 1849, 563-569 https://doi.org/10.1016/j.bbagrm.2014.07.004
  27. Ciro M, Prosperini E, Quarto M et al (2009) ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 69, 8491-8498 https://doi.org/10.1158/0008-5472.CAN-09-2131